Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. ...Read More
This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Be’er Ya’akov Mental Health Center, Israel
1 July, 2009
A clinical trial in Chronic Obstructive Pulmonary Disease Patients with an Addiction to Smoking, has begun at the Mental Health Center in Be’er Ya’akov, Israel.
The study aim is to assess the efficacy of Brainsway® Deep TMS device in inducing smoking cessation in chronic obstructive pulmonary disease patients. Between 90 and 120 patients are expected to participate in the trial. The trial will be a blinded placebo-controlled study.